We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
osei Group announces Formosa Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for APP13007 to commence a first-in-human (FIH) clinical trial in the United States.